Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEDI 5752

Drug Profile

MEDI 5752

Alternative Names: MEDI-5752; PD-l/CTLA-4 DuetMab

Latest Information Update: 25 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 24 Apr 2018 Phase-I clinical trials in Solid tumours in Australia (Parenteral) (NCT03530397)
  • 04 Apr 2018 Preclinical trials in Cancer in USA (Parenteral), prior to April 2018
  • 09 Nov 2017 MedImmune has patents pending for compositions and methods of making the proteins, nucleic acid molecules and methods for treating or preventing cancer in World
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top